Last reviewed · How we verify
Megestrol（Yining）
Megestrol acetate is a progestin that acts as a progesterone receptor agonist to suppress appetite and promote weight gain, and also has anti-tumor effects in hormone-responsive cancers.
Megestrol acetate is a progestin that acts as a progesterone receptor agonist to suppress appetite and promote weight gain, and also has anti-tumor effects in hormone-responsive cancers. Used for Cancer-related cachexia and anorexia in advanced malignancies, Hormone-responsive breast cancer, Endometrial cancer.
At a glance
| Generic name | Megestrol（Yining） |
|---|---|
| Also known as | Yining |
| Sponsor | The First Affiliated Hospital of Henan University of Science and Technology |
| Drug class | Progestin; hormonal agent |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Megestrol acetate binds to progesterone receptors, stimulating appetite and increasing caloric intake while promoting fat deposition. In oncology, it functions as a hormonal agent that can inhibit growth of hormone-responsive tumors, particularly in breast and endometrial cancers. The drug is commonly used to manage cancer-related cachexia and anorexia in advanced malignancies.
Approved indications
- Cancer-related cachexia and anorexia in advanced malignancies
- Hormone-responsive breast cancer
- Endometrial cancer
Common side effects
- Weight gain
- Thromboembolic events
- Hyperglycemia
- Adrenal insufficiency
- Vaginal bleeding
Key clinical trials
- Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |